Open Access<p>Clinical efficacy of cisplatin, dexamethasone, gemcitabine and pegaspargase (DDGP) in the initial treatment of advanced stage (stage III–IV) extranodal NK/T-cell lymphoma, and its correlation with Epstein-Barr virus</p>
Author(s) -
Qi Zhao,
Shanshan Fan,
Yu Chang,
Xiyang Liu,
Wencai Li,
Qianwen Ma,
Li Yang,
Yan Wang,
Lei Zhang,
Mingzhi Zhang
Publication year - 2019
Publication title -
cancer management and research
Language(s) - English
Resource type - Journals
ISSN - 1179-1322
DOI - 10.2147/cmar.s191929
Subject(s) - gemcitabine , medicine , dexamethasone , t cell lymphoma , stage (stratigraphy) , cisplatin , cancer research , lymphoma , oncology , chemotherapy , biology , paleontology
Objective: To evaluate the clinical efficacy and safety of the DDGP regimen in treating extranodal NK/T-cell lymphoma and investigate the correlation between Epstein-Barr virus (EBV)-DNA variation after treatment and the clinical efficacy of NK/T-cell lymphoma. Methods: Sixty-four patients with extranodal NK/T-cell lymphoma received DDGP regimen-based chemotherapy. Short-term and long-term clinical efficacy and adverse reactions were observed. The relationship between EBV-DNA changes before and after therapy and clinical efficacy was investigated. Results: After the DDGP regimen was used as the initial treatment, the short-term clinical efficacy included 39 complete remission (CR) (60.94%), 12 partial remission (PR) (18.75%), 2 stable disease (SD) (3.13%) and 11 progressive disease (PD) (17.18%). Objective response rate (ORR) was 79.69% and 82.82% for disease control rate (DCR). 3-year progression-free survival (PFS) was 62.00% and 3-year overall survive (OS) was 74.90%. Hemocytopenia was the predominant adverse effect. Between EBV-DNA positive group and its negative counterpart, a significant difference was noted in OS ( P =0.046), but no difference in ORR, DCR or PFS was observed. In the EBV-DNA positive group, ORR, DCR, PFS and OS were higher for patients whose EBV-DNA copy number decreased within a normal range than patients remained positive (93.33% versus 61.53%, P =0.041 for ORR; 93.33% versus 61.53%, P =0.041 for DCR, P =0.003 for PFS, P =0.017 for OS). The main adverse reactions included bone marrow suppression, gastrointestinal reaction and coagulation dysfunction, which were mitigated and treated after expectant or dose-decrement treatment. Conclusion: DDGP regimen can significantly improve the clinical prognosis of NK/T-cell lymphoma patients with tolerable adverse reactions. The variation in EBV-DNA is correlated with clinical efficacy and prognosis, which provides a theoretical basis for NK/T-cell lymphoma therapy. Clinical trial : In November 2011, this clinical trial was registered on the website: www.ClinicalTrials.gov (No. NCT01501149).